Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock Holdings Lifted by Barclays PLC

Barclays PLC lifted its position in Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) by 189.1% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 61,997 shares of the company’s stock after acquiring an additional 40,551 shares during the period. Barclays PLC owned about 0.10% of Acumen Pharmaceuticals worth $154,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. FMR LLC grew its position in Acumen Pharmaceuticals by 0.3% during the third quarter. FMR LLC now owns 2,028,117 shares of the company’s stock valued at $5,030,000 after purchasing an additional 6,014 shares in the last quarter. Geode Capital Management LLC grew its position in Acumen Pharmaceuticals by 6.5% in the third quarter. Geode Capital Management LLC now owns 864,528 shares of the company’s stock worth $2,144,000 after acquiring an additional 52,395 shares in the last quarter. State Street Corp grew its position in Acumen Pharmaceuticals by 18.3% in the third quarter. State Street Corp now owns 516,406 shares of the company’s stock worth $1,281,000 after acquiring an additional 79,841 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Acumen Pharmaceuticals in the second quarter worth approximately $818,000. Finally, Bank of New York Mellon Corp bought a new stake in Acumen Pharmaceuticals in the second quarter worth approximately $306,000. 71.01% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and issued a $15.00 price objective on shares of Acumen Pharmaceuticals in a research note on Wednesday, November 13th.

Insider Buying and Selling at Acumen Pharmaceuticals

In related news, CEO Daniel Joseph Oconnell sold 47,778 shares of the stock in a transaction that occurred on Friday, January 3rd. The shares were sold at an average price of $1.84, for a total value of $87,911.52. Following the sale, the chief executive officer now directly owns 454,707 shares in the company, valued at $836,660.88. This trade represents a 9.51 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last three months, insiders have sold 79,508 shares of company stock worth $146,556. Company insiders own 7.10% of the company’s stock.

Acumen Pharmaceuticals Stock Up 7.4 %

ABOS opened at $1.75 on Thursday. The firm’s 50-day simple moving average is $1.98 and its 200-day simple moving average is $2.46. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.43 and a current ratio of 10.43. Acumen Pharmaceuticals, Inc. has a twelve month low of $1.53 and a twelve month high of $5.09. The firm has a market cap of $105.14 million, a price-to-earnings ratio of -1.27 and a beta of 0.02.

Acumen Pharmaceuticals (NASDAQ:ABOS) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same period in the previous year, the company earned ($0.24) EPS. Equities research analysts anticipate that Acumen Pharmaceuticals, Inc. will post -1.56 EPS for the current fiscal year.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.